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ABSTRACT : 
Aims: Cluster of differentiation 36 (CD36) is involved in the development of 
non-alcoholic steatohepatitis (NASH). Excess CD36 facilitates liver cells taking fatty 
acid and activates inflammatory signals to promote hepatic steatosis and inflammation. 
However, CD36-deficiency paradoxically promotes non-alcoholic fatty liver disease by 
unknown mechanisms. We explored the probable molecular mechanism of hepatic 
inflammation induced by CD36 deficiency. Results: CD36 deletion in mice (CD36-/- 
mice) specifically increased monocyte chemotactic protein -1 (MCP-1) in hepatocytes, 
promoted macrophage migration to liver and aggravated hepatic inflammatory 
response and fibrosis. The nuclear expression of histone deacetylase 2 (HDAC2) 
which highly expresses in wild-type hepatocytes and has an inhibitory effect on acetyl 
histone 3 (H3) was reduced in CD36 deficiency hepatocytes. Consequently, the level of 
acetyl H3 binding to MCP-1 promoters was increased in CD36 deficient hepatocytes, 
causing hepatic specific MCP-1 transcriptional activation. Reduction of nuclear HDAC2 
in both CD36-/- mice liver and cultured hepatocytes was due to reduction of intracellular 
reactive oxygen species (ROS) level, while supplement of low concentration hydrogen 
peroxide (H2O2) overcame the suppression of HDAC2 caused by CD36 deficiency, 
decreasing MCP-1 gene transcription and microphage migration. Innovation: Our 
results provide first evidence that decreased ROS production by CD36 deletion was 
also harmful for livers. The fine balance of CD36 plays an important role in maintaining 
balances of hepatic ROS and nuclear HDAC2 which could be a potential new 
therapeutic strategy for the prevention of NASH development. Conclusion: CD36 
deficiency promoted the development of NASH by facilitating the transcription of 
MCP-1 in hepatocytes, due to the reduction of ROS and nuclear HDAC2.  
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INTRODUCTION 
Cluster of differentiation 36, also known as fatty acid translocase (FAT), belongs to 
the scavenger receptor family and is an integral membrane protein found on the 
surface of many cell types in vertebrates (36).  In its function as a facilitator of 
long-chain fatty acid transport and other biologically active lipids such as oxidized low 
density lipoprotein (ox-LDL), CD36 is believed to play an important role in the 
development of non-alcoholic fatty liver disease (NAFLD). Patients with NAFLD have 
elevated hepatic CD36 expression, which is positively correlated with liver fat content 
and insulin resistance (28). Experimental up-regulation of CD36 is sufficient to increase 
hepatic fatty acid uptake and triglyceride (TG) storage (6). Although the high 
expression of hepatic CD36 is closely related to NAFLD, CD36 deficiency 
paradoxically promotes the development of NAFLD. In the clinic, patients with genetic 
CD36 deficiency, which is relatively frequent in Asian and African populations, have 
been reported to exhibit hyperlipidemia, insulin resistance, and a propensity to develop 
symptoms of “metabolic syndrome” including fatty liver and atherosclerosis (18). When 
administered a high glucose or high fat diet, mice lacking CD36 exhibit increased 
plasma free fatty acid and TG levels and decreased hepatic insulin sensitivities (15). 
CD36 deletion exacerbates the steatosis by impairing hepatic triglyceride and ApoB 
secretion in homozygous ob/ob mice (31). These studies suggest that either CD36 
over-expression or deletion causes hepatic steatosis and that the function of CD36 as 
a fatty acid transporter may not explain the conflicting results regarding hepatic 
steatosis. 
CD36 has recently been identified as an important regulator of inflammatory 
response and function as a pattern recognition receptor (PRR) that conducts signals 
and activates inflammatory pathways such as Toll-like receptor (TLR), c-Jun N-terminal 
kinase(JNK) and Nuclear factor-кB (NF-кB) signals (17,22,36). Studies have shown 
that an increased expression of macrophage CD36 and other scavenger receptors 
contributes to hepatic macrophage infiltration and the development of non-alcoholic 
steatohepatitis (NASH) (5,6). However, in present study, we found that livers of mice 
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with global CD36 gene knockout exhibit an enigmatic increase of macrophage 
infiltration and inflammation, indicating a largely unknown role for CD36 in regulating 
macrophage migration.  
Macrophage migration and infiltration are regulated by chemokines and their 
receptors, particularly monocyte chemotactic protein-1 (MCP-1). MCP-1, also called 
CCL2, is a key chemokine in the development of NASH, and its up-regulation 
promotes macrophage accumulation, inflammation, fibrosis and steatosis (2). The 
gene expression of cytokines including MCP-1 are usually regulated by transcription 
factors such as NF-кB and repressors on the gene promoter and enhancer regions 
(37). In addition to NF-кB, epigenetic modification, especially histone acetylation, is the 
most common and important mechanism regulating the gene transcription of 
chemokines. It has been demonstrated that the NF-кB signal is inhibited by CD36 
deficiency (19), suggesting that increased macrophage migration and hepatic 
inflammation in CD36 deficiency are caused by NF-кB independent pathways. 
Acetyl histone3 (H3), which is usually inhibited by histone deacetylases (HDACs), 
is a transcription factor that binds to MCP-1 promoters. Co-operation of histone acetyl 
transferases (HATs) and histone deacetylases (HDACs) keeps the balance of histone  
acetylation: activation of HATs or inhibition of HDACs promotes gene transcription by 
inducing hyper-acetylation of core histones. The activities of HDACs are regulated by 
intracellular reactive oxygen species (ROS) levels (4), and CD36 has been reported to 
participate in the production of intracellular ROS. Holloway, G. P. et al suggested that 
CD36 is positioned on the outer mitochondrial membrane, upstream of long-chain 
acyl-CoA synthetase, thereby contributing to the regulation of mitochondrial fatty-acid 
transport and beta-oxidation (38). CD36 is also involved in transduction of intracellular 
signals such as mitogen-activated protein kinase (MAPK) signals to regulate ROS 
formation (27). Deletion of CD36 decreases intracellular ROS levels (9).  
In a “two-hit model” of NAFLD development, ROS-mediated inflammation has 
been considered to be the second hit, which has been proposed to cause the transition 
of hepatic steatosis to more severe NASH (10). The accumulation of lipids in 
hepatocytes impairs the oxidative capacity of mitochondria and increases the 
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generation of ROS, which triggers cell death and the production of inflammatory 
cytokines, ultimately resulting in the development of NASH (35). However, 
accumulating evidence has now indicated that ROS at low/moderate levels, especially 
the relatively stable hydrogen peroxide (H2O2) molecule, can function as an 
intracellular second messenger (39). Many ROS-mediated responses protect cells 
against oxidative stress and maintain "redox homeostasis". In addition, physiological 
ROS levels are necessary for the prevention of hepatic steatosis in zebrafish larvae 
(32). The dual roles of ROS in development of NAFLD are similar to that of CD36, 
suggesting the development of NASH in CD36 knockout mice is probably related to the 
decreased ROS production induced by CD36 deficiency. 
In this study, we explored whether CD36 deficiency inhibited hepatic HDACs by 
reducing ROS levels, and whether the decrease of HDACs increased acetyl histone3 
(H3) binding to MCP-1 promoters, consequently enhancing MCP-1 expression and 
increasing hepatic macrophage infiltration as well as promoting NASH development in 
murine models and in vitro cellular experiments. 
RESULTS 
CD36 deletion promoted the development of NASH in mouse livers.  
Age and weight matched wide-type (WT) mice and CD36 knockout (CD36-/-) mice 
were fed with a normal chow diet (NCD) or high fat diet (HFD) for 14 weeks. Data of 
liver sections showed that there was substantially more ballooning degeneration, 
inflammatory infiltration (hematoxylin &eosin staining, HE), lipid deposits (Oil Red O 
staining, ORO) and fibrosis (Sirius Red staining, SR) in CD36-/- mouse livers than in 
WT mouse livers in both the NCD and HFD groups (figure 1A). The mRNA expression 
of cytokines including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), 
interleukin -6 (IL-6) (figure 1B), TG content (figure 1C), mRNA of fibrosis markers 
including collagen I (col I) and collagen IV (col IV) (figure 1D) in CD36-/- mouse livers 
was much higher than in WT mouse livers, in both the NCD and HFD groups. These 
data indicated that the deletion of CD36 in mice promoted liver inflammation and 
fibrosis, which contributed to the development of NASH, regardless of the diet. 
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In contrast, results from cell culture experiments were markedly different from the 
in vivo data. The mRNA levels of cytokines (TNF-α, IL-1β, IL-6) in both the primary 
hepatocytes and liver macrophages were decreased in the CD36-/- group compared to 
WT group in the absence and presence of palmitate (PA) (figure 1E). HepG2 cells and 
THP-1 cells were transfected with negative control (NCi) or CD36 siRNA (CD36i) and 
treated with or without PA for 24 hours. PA treatment promoted the mRNA expression 
of cytokines (TNF-α, IL-1β, IL-6), which was attenuated by CD36 RNAi, both in HepG2 
cells and THP-1 cells (figure 1F). These results demonstrated that a deficiency of 
CD36 in cultured hepatocytes or macrophages alleviated PA induced inflammation.  
Increased macrophage infiltration is responsible for the elevated inflammation 
and fibrosis of CD36-/- mouse livers.  
The contrary results from liver and cultured cells indicated that the likely reason for 
elevated inflammation in CD36 deficient livers was due to the interaction between 
hepatocytes and macrophages. The immunohistochemistry staining showed that there 
were many more F4/80 (marker of macrophages) positive cells in CD36-/- mouse livers 
(figure 2A) than the WT mouse livers, in the absence and presence of HFD. The 
“crown-like” structure (indicated by the arrow in figure 2A), which was considered a 
common histological feature for steatohepatitis, was increased in the CD36-/- mouse 
livers compared to the WT mouse livers. The mRNA expression of F4/80 was also 
increased in livers of CD36-/- mice (figure 2A). 
We then administered gadolinium chloride (GdCl3), which inhibits macrophage 
migration to the liver, to mice that were fed with HFD for 10 weeks. GdCl3 is an earth 
metal salt that is widely used as an in vivo macrophage selective inhibitor (1) and has 
been shown to depress macrophage numbers and phagocytic activity in the livers of 
experimental animals (17,30). Interestingly, GdCl3 administration decreased 
macrophage infiltration (F4/80 staining and F4/80 mRNA levels), cytokines expression 
(mRNA of TNF-α, IL-1β and IL-6), and fibrosis (SR staining and mRNA levels of col I, 
col IV ) in CD36-/- mouse livers compared to WT mouse livers, whereas the lipid deposit 
(ORO staining and TG level) was still higher in CD36-/- mouse livers than that in WT 
mouse livers (figure 2B). These results indicated that the inhibition of hepatic 
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macrophage migration could alleviate the liver inflammation and fibrosis that was 
induced by CD36 deletion in vivo but it was not able to improve the steatosis in CD36-/- 
mouse livers.  
In an in vitro co-culture system, increasing macrophage migration induced by 
CD36 deletion in hepatocytes accounts for an increase in cytokine expression.  
Next, we set up a co-culture system of HepG2 and PMA differentiated THP-1 cells 
in transwell chambers to study two cell interactions without (-PA) or with palmitate 
treatment (+PA). Treatment of PA increased THP-1 migration (figure 3A: I vs V, II vs VI, 
III vs VII, IV vs VIII), which may be due to increased release of various monocytes/ 
macrophages chemoattracting agents (e.g. MCP-1, MIP-1, MIP-2 and nucleotides) in 
palmitate-treated cells (14,34). Interestingly, in the absence and presence of PA, CD36 
RNAi in THP-1 cells decreased THP-1 migration in the co-culture system (figure 3A III 
vs I, VII vs V), whereas CD36 RNAi in HepG2 increased THP-1 migration in the 
co-culture system (figure 3A II vs I, VI vs V). CD36 RNAi in HepG2 overrode the 
suppression caused by CD36 RNAi in THP-1 (figure 3A IV vs I, VIII vs V) suggesting 
that the overall biological effect of CD36 knock-down in both hepatocytes and THP-1 
was to increase macrophage migration. The same conclusion could be obtained from 
co-culture experiments of primary hepatocytes and liver macrophages isolated from 
WT and CD36-/- mice livers (figure S1). 
We then cultured HepG2 cells with different amounts of THP-1 cells, and both were 
transfected with CD36 siRNA to mimic the situation of increasing macrophage 
infiltration in CD36-deficient livers. The concentrations of cytokines in the supernatant 
of the co-culture system increased as the amounts of THP-1 cells in the upper 
chamber increased (figure 3B). This suggested that the overall effect of CD36 
deficiency is an inflammatory response due to large numbers of macrophage migration. 
Even the inflammatory responses of each cell (HepG2 and THP-1 cells) were 
diminished in CD36 deficiency conditions, as shown in figure 1F. 
Elevated MCP-1 expression in CD36-deficient hepatocytes should be 
responsible for the increased macrophage infiltration induced by CD36 deletion.  
We tested chemokine expression in different models. We found that the levels of 
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chemokines (including MCP-1, MIP-1 and MIP-2) were higher in CD36-/- mouse livers 
than in WT mouse livers, regardless of the diets administered to the mice (figure 4A). 
After suppression of macrophage migration by GdCl3, MIP-1 and MIP-2 mRNA in the 
liver decreased, whereas the MCP-1 mRNA was still higher in CD36-/- mouse livers 
than that in WT mouse livers (figure 4B). In HepG2 cells (figure 4C), MCP-1 mRNA 
was increased in the CD36i group compared with the NCi group in the absence or 
presence of PA, whereas MIP-2 mRNA was not different between the NCi and CD36i 
groups. In THP-1 cells (figure 4D), both the mRNA of MCP-1 and MIP-2 was 
decreased in the CD36i group compared to the NCi group. These in vitro results 
indicated that the elevated MCP-1 was specifically derived from CD36-deficient 
hepatocytes.  
We then designed a Chromatin Immunoprecipitation (ChIP) assay to test whether 
the expression of CD36 affected the level of acetyl histone3 (H3) binding to MCP-1 
promoters (figure 4E). In HepG2 cells, the level of acetyl H3 binding to MCP-1 
promoters was increased in the CD36i group compared to the NCi group. In contrast, 
in THP-1 cells, the level of acetyl H3 binding to MCP-1 promoters was decreased in the 
CD36i group. This corresponded to the changes of MCP-1 mRNA expression, 
indicating that CD36 tissue deletion specifically regulated MCP-1 expression through 
histone acetylation. 
CD36 deletion inhibited nuclear HDAC2 expression which regulated MCP-1 
expression in hepatocytes but not in macrophages. 
Next, we screened the expression of HDACs in mouse livers and cultured 
hepatocytes. HDAC2 mRNA expression decreased both in CD36-/- mouse livers and 
CD36 RNAi HepG2 cells (figure S2), indicating that increased MCP-1 expression was 
probably regulated by HDAC2. 
We then determined the expression and distribution of HDAC2 in mouse livers 
and cultured cells by IHC staining. We found that in WT mouse livers, HDAC2 positive 
signals were located in hepatocytes, especially in hepatocellular nuclei (as indicated by 
the solid line arrow in figure 5A), with no signals in non-parenchymal cells (as indicated 
by the dashed arrow in figure 5A). The positive HDAC2 staining was decreased in the 
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hepatocellular nuclei of CD36-/- mouse livers, indicating that CD36 deficiency 
attenuated the active expression of HDAC2 in hepatocytes (figure 5A). In primary 
cultures of mouse hepatocytes and HepG2 cells, an HDAC2 positive stain was 
observed in both the nuclei and cytoplasm of WT hepatocytes (figure 5B I) and in NCi 
HepG2 cells (figure 5C I) but was decreased in the nuclei of CD36-/- hepatocytes 
(figure 5B II) and CD36i HepG2 cells (figure 5C II). However, in mouse liver 
macrophages and THP-1 cells, the HDAC2 staining was very weak in the nuclei of all 
groups, including WT and CD36-/- liver macrophages (figure 5B III, IV), NCi and CD36i 
THP-1 cells (figure 5C III, IV), indicating that the levels of HDAC2 in macrophages 
were too low to be altered by CD36 deficiency. These observations were also 
confirmed by the results of Western blotting for nuclear HDAC2 in HepG2 and THP1 
cells (figure 5D and figure S3).  
Next, we utilized the HDAC inhibitor TSA and HDAC2 RNAi (HDAC2i) to 
down-regulate HDAC2 activities in HepG2 and THP-1 cells. In HepG2 cells, MCP-1 
mRNA was increased in the TSA or HDAC2i groups compared to the corresponding 
controls (figure 5E). In THP-1 cells, MCP-1 mRNA was not changed in the TSA or 
HDAC2i groups, compared to the control or NCi (figure 5F). Collectively, these results 
indicated that suppressed nuclear HDAC2, especially in hepatocytes, promoted 
MCP-1 expression. 
The disturbance of ROS production in CD36-deficient hepatocytes is 
responsible for the suppressed nuclear HDAC2 and increased expression of 
MCP-1.  
Because HDAC activity was reported to be closely related to intracellular ROS 
levels, we examined H2O2 levels in the liver tissue and the ROS content of cultured 
HepG2 cells. The H2O2 level in mouse livers in the HFD group was much higher than 
that in the NCD group. However, the H2O2 level in CD36
-/- mouse livers was much 
lower than that in WT mouse livers in both the NCD and HFD groups, indicating that 
CD36 deletion attenuated H2O2 production in the liver (figure 6A). In HepG2 cells, the 
ROS content was elevated in cells that were treated with PA and was decreased in 
CD36i HepG2 compared with NCi HepG2 (figure 6B). 
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We then treated HepG2 cells with the supplement of a low concentration 
(50μmol/L) of H2O2. Under the treatment of H2O2, nuclear HDAC2 staining appeared 
again in CD36i HepG2 cells (figure 6CII). Moreover, with the supplement of H2O2, 
MCP-1 mRNA expression was no longer increased in CD36i HepG2 cells (figure 6D). 
ChIP assays showed that level of acetyl H3 binding to MCP-1 promoters was clearly 
decreased, which was consistent with increased level of HDAC2 binding to MCP-1 
promoters, after treatment with 50μM H2O2 in CD36 RNAi HepG2 cells (figure 6E). 
Furthermore, CD36RNAi in HepG2 cells no longer promoted differentiated THP1 cells 
migration with the supplement of 50μM H2O2 (figure 6F). All these results suggested 
that CD36 deficiency promotes MCP-1 expression by inhibiting ROS production and 
HDAC2 and that maintaining a balance of hepatic ROS could prevent macrophage 
migration induced by CD36-deficiency. 
DISCUSSION 
Liver lobules are formed by parenchymal cells, such as hepatocytes, and 
non-parenchymal cells, including Kupffer cells, sinusoidal endothelial cells, and stellate 
cells. In NASH, the defining pathological element is hepatocellular injury, as evidenced 
by ballooning, Mallory bodies and apoptosis. Hepatocytes are considered to be a major 
source of the inflammatory response in NASH-affected liver (13). In addition to 
hepatocytes, activated Kupffer cells can launch a biochemical attack and initiate 
interactions with hepatocytes and other liver cells by releasing a variety of biologically 
active mediators including cytokines, chemokines, eicosanoids, proteolytic enzymes, 
ROS, and nitric oxide (3). An enlarged Kupffer cell pool, which is usually expanded by 
the migrated monocytes/macrophages from circulation, is believed to contribute to the 
onset of NASH by interacting with hepatocytes (24). However, the role of hepatocytes 
on macrophage migration remains unclear.  
In this study, we demonstrated that CD36 deletion attenuated the expression of 
inflammatory cytokines both in hepatocytes and macrophages when they were 
cultured alone. However, when hepatocytes and macrophages were together in liver 
tissue or in an in vitro co-culture system, CD36 deletion could not attenuate but instead 
 Page 10 of 39
A
nt
io
xi
da
nt
s &
 R
ed
ox
 S
ig
na
lin
g
CD
36
 d
ef
ic
ie
nc
y 
ag
gr
av
at
es
 m
ac
ro
ph
ag
e i
nf
ilt
ra
tio
n 
an
d 
he
pa
tic
 in
fla
m
m
at
io
n 
by
 u
p-
re
gu
la
tin
g 
M
CP
-1
 ex
pr
es
sio
n 
of
 h
ep
at
oc
yt
es
 th
ro
ug
h 
H
D
A
C2
-d
ep
en
da
nt
 p
at
hw
ay
 (d
oi:
 10
.10
89
/ar
s.2
01
6.6
80
8)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
11 
11 
 
A
n
ti
o
x
id
an
ts
 a
n
d
 R
ed
o
x
 S
ig
n
al
in
g
 
C
D
3
6
 d
ef
ic
ie
n
cy
 a
g
g
ra
v
at
es
 m
ac
ro
p
h
ag
e 
in
fi
lt
ra
ti
o
n
 a
n
d
 h
ep
at
ic
 i
n
fl
am
m
at
io
n
 b
y
 u
p
-r
eg
u
la
ti
n
g
 M
C
P
-1
 e
x
p
re
ss
io
n
 o
f 
h
ep
at
o
cy
te
s 
th
ro
u
g
h
 H
D
A
C
2
-d
ep
en
d
an
t 
p
at
h
w
ay
 (
d
o
i:
 1
0
.1
0
8
9
/a
rs
.2
0
1
6
.6
8
0
8
) 
T
h
is
 p
ap
er
 h
as
 b
ee
n
 p
ee
r-
re
v
ie
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
li
ca
ti
o
n
, 
b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
g
o
 c
o
p
y
ed
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. 
T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
promoted cytokine secretion as a consequence of increased macrophage infiltration. 
CD36 deletion in hepatocytes alone or both in hepatocytes and macrophages 
increased macrophage migration and inflammatory cytokine secretion in a co-culture 
system of hepatocytes and macrophages. Targeted inhibition of macrophage infiltration 
into the liver by GdCl3 administration effectively relieved the increased hepatic 
inflammation and fibrosis induced by CD36 deletion. These results suggest that CD36 
deletion could induce an increased macrophage pool in the liver and increase the 
interaction between hepatocytes and macrophages. This could completely 
compensate for the decrease in cytokine secretion by CD36 deletion in hepatocytes 
and macrophages. In addition, CD36-/- decreased fatty acid up-take, but CD36-/- did not 
reduce lipid accumulation in mouse livers, probably because of a deficiency in very 
low-density lipoprotein (VLDL) excretion by hepatocytes (31). The overall effect of 
CD36 deficiency promotes hepatic inflammatory response, lipid accumulation and liver 
fibrosis. 
The role of CD36 in the regulation of macrophage migration has been studied 
extensively in models of arthrosclerosis; however, the results are controversial (20). A 
study from Harb (16) and Kuchibhotla (25) has suggested that CD36 expression 
promotes macrophage migration, whereas the results from Park (33) suggest that the 
engagement of CD36 by ox-LDL inhibits macrophage migration. One potential 
explanation for these apparently conflicting results is that different ligands binding to 
CD36 may promote different intracellular signaling pathways related to cellular 
migration and inflammation. Other than the recognition of different ligands, CD36 is 
also expressed in different cells and tissues. In this study, we first demonstrated that 
CD36 deletion in hepatocytes promoted macrophage migration, whereas CD36 
deletion in hepatic macrophages inhibited macrophage migration, indicating that the 
CD36 of parenchymal cells or non-parenchymal cells might play different roles in 
hepatic inflammation. The different regulation of macrophage migration by CD36 
depends on the differential expression of MCP-1 in different cells.  
MCP-1 expression can usually be stimulated by cytokines such as TNF-α (24)，but 
in this study, MCP-1 was elevated, whereas cytokines and other chemokines such as 
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MIPs were decreased in CD36-/- mouse livers after the inhibition of liver macrophages. 
This indicates that MCP-1 in CD36-/- mouse livers was elevated prior to other cytokines 
and was derived from hepatocytes. The result was confirmed by in vitro experiments 
showing that MCP-1 was elevated whereas cytokines and MIPs were decreased in 
CD36 RNAi HepG2 cells. These changes were consistent with the results of a 
macrophage migration assay. Thus, this is the first demonstration that MCP-1 derived 
from hepatocytes plays a key role in hepatic macrophage infiltration and hepatic 
inflammation in CD36 deficiency models.  
Furthermore, we explored the mechanism by which CD36 tissue deletion 
specifically induced the expression of MCP-1 in hepatocytes but not in macrophages. 
We demonstrated that CD36 deletion regulated MCP-1 expression at the 
transcriptional level by changing the acetylation of histones binding to the MCP-1 
promoters. A balance of HATs and HDACs controls the histone acetylation. 
Approximately 18 different HDACs have been identified and grouped into 2 families 
and 4 classes in eukaryotic cells: Zn-dependent HDACs including HDAC1 through 11 
and NAD-dependent Sirtuins (8). Many studies have shown that MCP-1 expression is 
regulated by HDACs. In hepatic stellate cells, HDAC1 is recruited to specific regulator 
regions of MCP-1 and suppress MCP-1 expression (12); HDAC3 has been reported to 
mediate allergic skin inflammation by regulating MCP-1 expression(23). Many HDACs 
are involved in the development of NASH, such as HDAC3 and SIRT1 (26). However, 
the regulation of MCP-1 by HDACs and CD36 deficiency remains unclear. We found 
that HDAC2 mRNA was decreased after screening for the expression of 11 classic 
HDACs in CD36-/- mouse livers and CD36-deficient hepatocytes. HDAC2 belongs to 
class I HDAC (comprisingHDAC1, HDAC2, HDAC3 and HDAC8), which is ubiquitously 
expressed in all tissue types (7). HDAC2, with its highly related sister protein HDAC1, 
is present in the mammalian nucleus as part of stable multi-protein complexes, such as 
Sin3A, NuRD and CoREST complexes (21). Simultaneous deletion of HDAC1 and 
HDAC2 in T-cells and embryonic stem cells causes a 50% decrease in total HDAC 
activity therefore; they are recognized as the predominant HDACs in the mammalian 
nucleus (11). We demonstrated that in the mouse liver, HDAC2 is primarily expressed 
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in hepatocytes and only rarely in non-parenchymal cells. CD36 deletion clearly 
inhibited nuclear expression of HDAC2 in hepatocytes but had no impact on the 
expression of HDAC2 in macrophages. MCP-1 mRNA expression was promoted by 
the treatment of the HDAC inhibitor TSA or HDAC2 RNAi in hepatocytes rather than in 
macrophages. Furthermore, CD36 deletion in hepatocytes promoted MCP-1 
expression by suppressing the nuclear expression of HDAC2, which does not apply to 
macrophages because of the extremely low expression of HDAC2.  
Numerous studies have shown that HDACs are redox-sensitive. The relationship 
between ROS, HDAC activity, and acetylation status may depend on the intensity of 
ROS, endogenous HDAC activity, and the experimental cell types used (29). ROS has 
a bi-directional impact on the activity of HDACs: strong oxidative stress induces 
hypoacetylation, while weak oxidative stress induces hyperacetylation, even in the 
same cell line (4). A decreased oxygen environment inhibits the activities of HDACs 
(40). 
CD36 is important to maintain intracellular ROS homeostasis, as it could modulate 
ROS production through mediating lipid uptake, facilitating fatty acid into mitochondria 
for oxidation, and activating redox signaling such as MAPK (27). In this study, we found 
that CD36 deletion decreased the hepatic ROS levels in vivo and in vitro. 
Supplementation with ROS (H2O2) improved the nuclear expression of HDAC2, 
decreased acetyl H3 binding to MCP-1 promoters, and eliminated the elevation of 
MCP-1 expression in CD36 deficient hepatocytes. This suggests that the decreased 
ROS level by CD36 deletion contributes to the suppressed nuclear HDAC2 and 
elevated MCP-1 in CD36 deficient hepatocytes, which promoted hepatic macrophage 
infiltration and the development of NASH in CD36-/- mice. The over-production of ROS 
has been regarded to be a deleterious process that induces an inflammatory response 
and pathological conditions. Our data suggest that decreased ROS production by 
CD36 deletion was also harmful for mouse livers, making them susceptible to 
developing NASH by suppressing the expression of HDAC2 and promoting the 
expression of MCP-1 in hepatocytes.  
In conclusion, excess CD36 facilitates the transport by liver cells of fatty acids and 
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activates inflammatory signals, thereby promoting hepatic steatosis and inflammation; 
whereas, deletion of CD36 induces hepatic macrophage infiltration and inflammation 
by increasing the expression of MCP-1 in hepatocytes because of reducing ROS 
production and suppressing nuclear HDAC2 (figure 7). CD36 deficiency cannot 
alleviate the development of NASH in mouse models. The physiological levels of CD36 
in hepatocytes are important to keep a balance of ROS, macrophage migration, and 
the inflammatory response. Maintaining a balance of hepatic ROS and nuclear HDAC2 
could be a potential new therapeutic strategy for the prevention of NASH development 
in CD36-deficient individuals. 
 
INNOVATION: 
It is generally acceptable that over-production of ROS has been regarded to be a 
deleterious process that induces an inflammatory response, causing the second hit for 
NASH development in the “two-hit model”. However, we demonstrated that decreased 
ROS production by CD36 deletion was also harmful for livers. The fine balance of 
CD36 plays an important role in maintaining balances of hepatic ROS and nuclear 
HDAC2 which could be a potential new therapeutic strategy for the prevention of 
NASH development. 
 
MATERIALS AND METHODS 
Animals and diets 
CD36 knockout mice created on a C57BL/6J background were kindly provided by Dr. 
Maria Febbraio (Lerner Research Institute, U.S.). Mice were randomly fed a normal 
chow diet (NCD) composed of 10% kcal% fat (Research Diets Inc., NJ, U.S.) or a high 
fat diet with 1.25% cholesterol and 0.5% cholic acid (HFD) containing 40% kcal% fat 
(Research Diets Inc., NJ, U.S.) for 14 weeks before sacrifice. To inhibit the function of 
liver macrophages, WT and CD36-/- mice were administered 1% gadolinium chloride 
(GdCl3, Sigma) solution (10 mg/kg) twice a week through intra-peritoneal injection and 
fed with HFD for 10 weeks before sacrifice. All animals received humane care 
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according to the criteria outlined in the “Guide for the Care and Use of Laboratory 
Animals” prepared by the National Academy of Sciences and published by the National 
Institutes of Health (NIH publication 86-23 revised 1985).  
Cell culture and treatments  
HepG2 cells were cultured in DMEM with 10% fetal bovine serum (FBS, Equetech Bio 
Inc, TX, U.S.), and THP-1 cells were cultured in RPMI 1640 medium containing 10% 
FBS, in an incubator kept at 37˚C with5% CO2. Before experiments, THP-1 cells were 
differentiated into macrophages by incubation with 200 nmol/L phorbol 12-myristate 
13-acetate (PMA, Sigma) for 48 h. The preparation of primary hepatocytes and liver 
macrophages from mouse livers followed the protocol in the supplementary material. 
Before harvesting, the cells were pre-incubated for at least 12 hours in serum-free 
medium and then incubated for 24 hours in serum-free medium (control) or serum-free 
medium containing 0.16 mmol/L sodium palmitate (PA, Sigma), or 100μmol/L 
trichostatin A (TSA, Millipore), or 50μmol/L H2O2 solution (Sigma). siRNA was 
transfected using X-tremeGENE siRNA Transfection Reagent (Roche) according to the 
manufacturer’s instructions.  
Co-culture system and migration assay  
HepG2 cells and differentiated THP-1 cells were co-cultured using 6-well transwell 
plate inserts with a 0.4μm porous membrane (Corning) to separate the lower chamber 
of the serum-starved HepG2 from the upper chamber of serum-starved THP-1. For the 
in vitro migration assay, transwell inserts with an 8μm porous membrane (Corning) 
were used. After allowing migration for 16 hours, the migratory cells on the lower side 
of the membrane were stained with 4,6-diamidino-2-phenylindole. The average 
number of migratory cells in each well was counted from four random fields under the 
microscope. The cytokine content in the supernatants of the co-culture system was 
determined by Milliplex Analyst (Millipore). 
Preparation of primary hepatocytes and macrophages from mouse livers  
We anesthetized 8 week old WT or CD36-/-mice and opened the abdominal cavity. We 
cannulated the portal vein and immediately perfused it with modified Hanks’ buffered 
saline. The liver was infused with a collagenase solution (100 mg collagenase in 150 
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ml Hank’s buffer) by a peristaltic pump at a rate of 1.5 ml/min for 20 minutes. The liver 
was removed and sliced into small pieces which were placed in collagenase solution 
and filtered with a 100 mm cell filter. The cell suspension was centrifuged at 800rpm for 
5 min, and the deposits were primary hepatocytes. The supernatant was placed into 
another tube and centrifuged twice at 2000rpm for 5 min. The deposits were 
macrophages. The hepatocytes and macrophages were cultured in DMEM containing 
20% FCS and maintained in an incubator at 37°C,5% CO2. 
Liver histology  
Paraffin-embed liver sections(4μm) were stained with hematoxylin and eosin (HE). For 
immunohistochemistry, the sections were incubated in 3% hydrogen peroxide followed 
by 1% BSA in PBS, and then overnight (4˚C) with anti-CD36 (1:100, Santa Cruz) or 
anti-F4/80 (1:50, Biolegend) or anti-HDAC2(1:100, Millipore). Acommercial kit (Zsbio, 
China) was used to perform the histochemical reaction and was counterstained with 
hematoxylin. For Oil Red O staining (ORO), frozen sections were stained for 30 
minutes then counterstained with hematoxylin. For Picro-Sirius Red staining (SR), 
sections were incubated with 0.5% Sirius Red F3B (Sigma) in saturated aqueous picric 
acid for at least 1 hour, then washed with 0.1% acetic acid solution 3 times. Results 
were examined by light microscopy. 
Real time PCR  
Total RNA was extracted from the liver of mice or cultured cells by RNAiso Plus 
reagent (Takara). By using a cDNA synthesis kit (Takara), 1.0μg of total RNA was 
converted to first strand complementary DNA in a 20μl reaction system. 
Real-time-PCR was performed in a real-time PCR machine (Bio-Rad) using SYBR 
Green dye. The thermal cycling program was 5 min at 95˚C for enzyme activation and 
40 cycles of denaturation for 15 s at 95˚C, 15 s annealing at 55˚C and 15 s extension 
at 72˚C. Beta-actin was used as an internal control gene. All the primers were 
designed by Primer Express Software V2.0 (Applied Biosystems, UK) (See also Table 
S1 and S2). 
Chromatin immunoprecipitation (ChIP) assay  
The procedure was performed according to the manufacturer’s instructions with a 
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Magna ChIP G kit (Millipore). The MCP-1 promoter-specific primers are shown in 
Supplementary Material (See Table S1). 
TG content, ROS and H2O2 assays 
These assays were performed according to the manufacturer’s instructions with a TG 
Assay kit (Millipore) and hydrogen peroxide assay kit (Beyotime). For ROS assays, 
cells were incubated with DCFH for 40min and relative fluorescence unit (RFU) of DCF 
were measured at indicated time using an ROS assay kit (Beyotime). 
Western blotting 
Nuclear protein was extracted using a nuclear extraction kit (Abcam). Equal amounts 
of nuclear protein was resolved on SDS-PAGE and transferred to PVDF membrane 
(Millipore). The blots were incubated with the primary antibodies anti-HDAC2 
(Millipore), anti-Lamin (Proteintech) and secondary antibodies HRP-conjugated goat 
anti-rabbit IgG (Zsbio). Blotted proteins were detected with the Odyssey Imaging 
System (LI-COR Biosciences). Quantification was performed with Image J software. 
Statistical analysis  
All the data were analyzed by Graph Pad Prism 5.0. A t-test was used to compare the 
statistical relevance of the two groups. For groups of three or more, analysis of 
variance (one-way ANOVA) with post test using Tukey was performed. Two-way 
ANOVA was used to determine the interactions between two factors. Data are 
expressed as the mean ± standard error of the mean (SEM). P <0.05 was considered 
to be significant. All the data were from at least three separate experiments. 
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Abbreviations Used: 
1. CD36 = cluster of differentiation 36;  
2. NASH = non-alcoholic steatohepatitis;  
3. MCP-1 = monocyte chemotactic protein-1;  
4. H3 = histone3;  
5. HDAC = histone deacetylase;  
6. ROS = reactive oxygen species;  
7. NAFLD = non-alcoholic fatty liver disease;  
8. TG = triglyceride;  
9. ApoB = apolipoprotein B;  
10. PRR = pattern recognition receptor;  
11. TLR = toll-like receptor;  
12. JNK = c-Jun N-terminal kinase;  
13. NF-кB = nuclear factor-кB;  
14. HAT = histone acetyl transferases ;  
15. MAPK = mitogen-activated protein kinase;  
16. FAT = fatty acid translocase;  
17. WT = wide type ;  
18. NCD = normal chow diet； 
19. HFD = high fat diet； 
20. GdCl3 = gadolinium chloride； 
21. FCS = fetal calf serum;  
22. PMA = phorbol 12-myristate 13-acetate;  
23. PA = palmitate;  
24. TSA = Trichostatin A；  
25. ChIP = chromatin immunoprecipitation;  
26. H2O2 = hydrogen peroxide;  
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27. MIP-1 = macrophage inflammatory protein-1； 
28. MIP-2 = macrophage inflammatory protein-2；  
29. NC = negative control； 
30. VLDL = very low-density lipoprotein 
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Figure1. CD36 deletion promoted the development of NASH in mouse livers. 
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(A) The histological changes in liver tissue were examined by hematoxylin-eosin 
(HE) staining. The lipid accumulation in the livers was verified by oil red O (ORO) 
staining. Liver fibrosis was examined by Sirius Red (SR) staining.   (B) The mRNA 
expression of cytokines (TNF-α, IL-1β, IL-6) in the liver tissues of WT and CD36-/- 
mice was examined by real time PCR, n≥5, *P<0.05 versus WT in NCD, #P<0.05 
versus WT in HFD.  (C) Triglyceride (TG) content was determined by an ELISA kit, 
n≥5, *P<0.05 versus WT in NCD, #P<0.05 versus WT in HFD.  (D) The mRNA 
expression of fibrosis markers (collagen I, collagen IV) was examined by real time PCR, 
n≥5, *P<0.05 versus WT in NCD, #P<0.05 versus WT in HFD.  (E) The mRNA 
expression of cytokines in primary hepatocytes and liver macrophages from WT and 
CD36-/- mice treated with or without 0.16 mmol/L palmitate(PA) were examined by real 
time PCR, n>5, *P<0.05 versus WT -PA, #P<0.05 versus WT +PA.  (F) The mRNA 
expression of cytokines in HepG2 and THP-1 cells transfected with NC siRNA (NCi) or 
CD36 siRNA (CD36i) were examined by real time PCR, n>5, *P<0.05 versus NCi -PA, 
#P<0.05 versus NCi +PA. To see this illustration in color, the reader is referred to the 
web version of this article at www.liebertonline.com/ars. 
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Figure2. Increased macrophage infiltration is responsible for the elevated 
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inflammation and fibrosis in CD36-/- mice livers. 
(A) Immunohistochemistry staining of macrophage marker F4/80 in liver sections of 
WT and CD36-/- mice fed with NCD or HFD. And mRNA of F4/80 of these groups was 
tested by RT-PCR, n≥3, *P<0.05 versus WT and NCD, #P<0.05 versus WT and HFD.  
(B) Liver sections from WT and CD36-/- mice administered by gadolinium chloride 
(GdCl3) and fed with HFD were stained by IHC of F4/80, HE, SR, and ORO. The 
mRNA expression of F4/80, cytokines and collagens was examined by real time PCR, 
and TG content was determined by ELISA kit, n≥5, *P<0.05 versus control (WT). To 
see this illustration in color, the reader is referred to the web version of this article at 
www.liebertonline.com/ars. 
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Figure3. In vitro co-culture system, increasing macrophage migration induced 
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by CD36 deletion in hepatocytes accounts for the increasing cytokine 
expression. 
(A) Migrated THP-1 cells co-cultured with HepG2 cells after NCi or CD36i were stained 
by 4,6-diamidino-2-phenylindole and counted, *P<0.05 versus NCi HepG2 with NCi 
THP-1. (B) The cytokine contents in the supernatant of the co-culture system in 
whichCD36i HepG2 cells co-cultured with increasing amounts of CD36i THP-1 cells 
were determined by Milliplex Analyst, n=5, *P<0.05 versus THP-1. To see this 
illustration in color, the reader is referred to the web version of this article at 
www.liebertonline.com/ars. 
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Figure4. Elevated MCP-1 expression in CD36-deficient hepatocytes could be 
 Page 28 of 39
A
nt
io
xi
da
nt
s &
 R
ed
ox
 S
ig
na
lin
g
CD
36
 d
ef
ic
ie
nc
y 
ag
gr
av
at
es
 m
ac
ro
ph
ag
e i
nf
ilt
ra
tio
n 
an
d 
he
pa
tic
 in
fla
m
m
at
io
n 
by
 u
p-
re
gu
la
tin
g 
M
CP
-1
 ex
pr
es
sio
n 
of
 h
ep
at
oc
yt
es
 th
ro
ug
h 
H
D
A
C2
-d
ep
en
da
nt
 p
at
hw
ay
 (d
oi:
 10
.10
89
/ar
s.2
01
6.6
80
8)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
29 
29 
 
A
n
ti
o
x
id
an
ts
 a
n
d
 R
ed
o
x
 S
ig
n
al
in
g
 
C
D
3
6
 d
ef
ic
ie
n
cy
 a
g
g
ra
v
at
es
 m
ac
ro
p
h
ag
e 
in
fi
lt
ra
ti
o
n
 a
n
d
 h
ep
at
ic
 i
n
fl
am
m
at
io
n
 b
y
 u
p
-r
eg
u
la
ti
n
g
 M
C
P
-1
 e
x
p
re
ss
io
n
 o
f 
h
ep
at
o
cy
te
s 
th
ro
u
g
h
 H
D
A
C
2
-d
ep
en
d
an
t 
p
at
h
w
ay
 (
d
o
i:
 1
0
.1
0
8
9
/a
rs
.2
0
1
6
.6
8
0
8
) 
T
h
is
 p
ap
er
 h
as
 b
ee
n
 p
ee
r-
re
v
ie
w
ed
 a
n
d
 a
cc
ep
te
d
 f
o
r 
p
u
b
li
ca
ti
o
n
, 
b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
g
o
 c
o
p
y
ed
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. 
T
h
e 
fi
n
al
 p
u
b
li
sh
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
responsible for the increased macrophage infiltration induced by CD36 deletion. 
The mRNA expression of chemokines (MCP-1, MIP-1,MIP-2) in mouse liver 
without Gdcl3 administration(A), mouse liver with Gdcl3 administration(B), CD36 RNAi 
HepG2 cells(C) and CD36 RNAi THP-1 cells(D) were measured by real time PCR, n≥5, 
*P<0.05 versus corresponding control(WT in NCD or NCi -PA), #P<0.05 versus WT in 
HFD or NCi +PA. (E) Chromatin immunoprecipitation (ChIP) was used to examine the 
levels of acetyl histones binding to MCP-1 promoters in NCi or CD36i HepG2 cells and 
THP-1 cells. 
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Figure5. CD36 deletion inhibited nuclear HDAC2 expression, which regulated 
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MCP-1 mRNA expression in hepatocytes, but not in macrophages. 
Expression and distribution of HDAC2 in liver tissue (A), primary hepatocytes and liver 
macrophages (B), HepG2 and THP1 cells (C) were determined by IHC. Nuclear 
HADC2 positive cells were counted, and relative density of nuclear HDAC2 were 
measured by Image J, n≥5, *P<0.05 versus the corresponding controls (WT or NCi). (D) 
The protein expression of nuclear HDAC2 in HepG2 and THP1 cells were determined 
by western blotting. The mRNA expression of chemokines (MCP-1) in HepG2 cells (E) 
and THP-1 cells (F) treated with TSA or HDAC2 RNAi was determined by real time 
PCR. n≥3, *P<0.05 versus the corresponding controls (TSA=0 or NCi). To see this 
illustration in color, the reader is referred to the web version of this article at 
www.liebertonline.com/ars. 
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Figure6. The disturbance of ROS production in CD36-deficient hepatocytes is 
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responsible for the suppression of nuclear HDAC2 and the increased expression 
of MCP-1 mRNA. 
(A) H2O2 content in liver tissue was verified by spectrophotometer, n=6, *P<0.05 
versus the control (WT in NCD), #P<0.05 versus WT in HFD.  (B) ROS in HepG2 cells 
was labeled by fluorescent probes and tested by spectrophotometer at indicated time, 
n=6, *P<0.05 versus the control (NCi,-PA), #P<0.05 versus NCi +PA. (C) HepG2 cells 
transfected by NC or CD36 siRNA were treated with serum-free medium containing 
50μmol/L H2O2 for 24 hours. IHC staining of HDAC2 was performed to test the nuclear 
expression of HDAC2.  (D) The mRNA expression of MCP-1 in HepG2 cells treated 
with 50μmol/L H2O2 were determined by real time PCR, n≥3. (E) ChIP assay of acetyl 
H3 and HDAC2 binding to MCP-1 promoters in HepG2 cells treated with or without 
H2O2 (50μmol/L). (F) With the supplement of H2O2, migrated THP-1 cells co-cultured 
with NCi or CD36i HepG2 cells were stained by 4,6-diamidino-2-phenylindole and 
counted, *P<0.05 versus NCi HepG2 with NCi THP-1. To see this illustration in color, 
the reader is referred to the web version of this article at www.liebertonline.com/ars. 
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Figure7: The mechanism of CD36 deficiency promoting the development of 
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NASH. 
CD36 deficiency decreased ROS production in hepatocytes, which removed the 
inhibition of HDAC2 on the level of acetyl-H3 binding to the MCP-1 promoter, initiating 
the transcription of the MCP-1 gene. Sequentially the increased expression of MCP-1 
from hepatocytes enhanced the infiltration of macrophages in the liver, which elevated 
cytokine excretion and triggered the development of NASH in CD36 deficient 
individuals. To see this illustration in color, the reader is referred to the web version of 
this article at www.liebertonline.com/ars. 
 
 
Figure legends for supplementary figures: 
Figure S1. Migration assay of liver macrophages co-cultured with primary 
hepatocytes. 
Primary liver macrophages isolated from WT or CD36-/- mice livers were 
co-cultured with primary hepatocytes isolated from WT or CD36-/- mice livers, with or 
without PA treatment. The migrated macrophages were stained by 
4,6-diamidino-2-phenylindole and counted at least 5 fields, *P<0.05 versus WT 
macrophages with WT hepatocytes. 
Figure S2. mRNA levels of HDACs in mice liver and cultured cells. 
mRNA levels of HDACs (HDAC1-11) in mice livers (A) and HepG2 cells (B) were 
examined by real time PCR, n≥5, *P<0.05 versus WT in NCD or NCi. 
Figure S3. The full unedited blot of nuclear HDAC2 in HepG2 and THP1 cells. 
Table S1: PCR Primers of human gene.  
Gene-specific primers of human Sequences(5’ to 3’) 
Human β-actin Forward: 5′-CCTGGCACCCAGCACAAT-3′ 
 Reverse: 5′-GCCGATCCACACGGAGTA-3′ 
Human TNF-α Forward: 5′-AGGACCAGCTAAGAGGGAGA-3′ 
 Reverse: 5′-CCCGGATCATGCTTTCAGTG-3′ 
Human IL-1β Forward: 5′-GGAGAATGACCTGAGCACCT-3′ 
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 Reverse: 5′-GGAGGTGGAGAGCTTTCAGT-3′ 
Human IL-6 Forward: 5′-AGTCCTGATCCAGTTCCTGC-3′ 
 Reverse: 5′-AAGCTGCGCAGAATGAGATG-3′ 
Human Collagen Ⅰ Forward: 5′-GGAAACGTAAGCGTGGTGAAA-3′ 
 Reverse: 5′- TGTCACACAGTTGGCAAGGAA-3′ 
Human Collagen Ⅳ Forward: 5′-CTTGCCTTCCCGTATTTAGCA-3′ 
 Reverse: 5′-GATCTGTCGTTTCTCTGGGCATA-3′ 
Human MCP-1 Forward: 5′-CAAGCAGAAGTGGGTTCAGGAT-3′ 
 Reverse: 5′-TCTTCGGAGTTTGGGTTTGC-3′ 
Human MIP-2α Forward: 5′- AAGATGCTGAAAAATGGCAAATC-3′ 
 Reverse: 5′- GAACAGCCACCAATAAGCTTCCT-3′ 
Human MCP-1 promoter 1 Forward: 5′- ACCCTCATTTTCCCCATA-3′ 
 Reverse: 5′- AGGCCATCTCACCTCATC-3′ 
Human MCP-1 promoter 2 Forward: 5′- AATGCGGTCCACCAAGTT-3′ 
 Reverse: 5′- AATGGCTGGGCTGAGTTT-3′ 
Human MCP-1 promoter 3 Forward: 5′- CTAGCAACAGCCTCCTAA-3′ 
 Reverse: 5′- CTGGGTTAGTCTCAGCCT-3′ 
Human HDAC1 Forward: 5′- CGCCAAGTGTGTGGAATTTG-3′ 
 Reverse: 5′- GCCTCCCAGCATCAGCATA-3′ 
Human HDAC2 Forward: 5′-ACATGAGCAATGCGGAGAAAT -3′ 
 Reverse: 5′-TCTGCCATCTTGTGGTACAGTGA -3′ 
Human HDAC3 Forward: 5′-CCTTTTCCAGCCGGTTATCA-3′ 
 Reverse: 5′- ACAATGCACGTGGGTTGGT-3′ 
Human HDAC4 Forward: 5′- TCAGATCGCCAACACATTCG-3′ 
 Reverse: 5′- ACGGGAGCGGTTCTGTTAGA-3′ 
Human HDAC5 Forward: 5'-TTGCCTGGGCCCTACGA-3' 
 Reverse: 5'-GGGTTCAGAGGCTGTTTTGC-3' 
Human HDAC6 Forward: 5′- TCGCTGCGTGTCCTTTCAG-3′ 
 Reverse: 5′- -GCTGTGAACCAACATCAGCTCTT -3′ 
Human HDAC7 Forward: 5′- CAAGAGCAAGCGAAGTGCTGTA-3′ 
 Reverse: 5′- TTCAGAATCACCTCCGCTAGCT-3′ 
Human HDAC8 Forward: 5'-CGCTGGTCCCGGTTTATATC-3' 
 Reverse: 5'-TGGCCAGGGAGTCACACAT-3' 
Human HDAC9 Forward: 5'-GCCCACCACACATCATTGG-3' 
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 Reverse: 5'-AATGTGTACTTGTAGGATGGAGATGTTC-3' 
Human HDAC10 Forward: 5'-TGACCCCAGCGTCCTTTACT-3' 
 Reverse: 5'-CCAGAAGCGCCCATGCT-3' 
Human HDAC11 Forward: 5'-ACAACCCAGCTGTACCAGCAT-3' 
 Reverse: 5'-CGCGGCGAGTACACGATT-3' 
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Table S2: PCR Primers of mouse gene.  
Gene-specific primers of human Sequences(5’ to 3’) 
Mouse β-actin Forward: 5′-CGATGCCCTGAGGCTCTTT-3′ 
 Reverse: 5′-TGGATGCCACAGGATTCCAT-3′ 
Mouse TNF-α Forward: 5′-CAGCCGATGGGTTGTACCTT-3′ 
 Reverse: 5′-GGCAGCCTTGTCCCTTGA-3′ 
Mouse IL-1β Forward: 5′-ACTCATTGTGGCTGTGGAGA-3′ 
 Reverse: 5′-TTGTTCATCTCGGAGCCTGT-3′ 
Mouse IL-6 Forward: 5′- CCACGGCCTTCCCTACTTC-3′ 
 Reverse: 5′- TTGGGAGTGGTATCCTCTGTGA-3′ 
Mouse Collagen Ⅰ Forward: 5′-CAACCTGGACGCCATCAAG-3′ 
 Reverse: 5′- CAGACGGCTGAGTAGGGAACA-3′ 
Mouse Collagen Ⅳ Forward: 5′- CCGAGCCAGTCCATTTATAGAATG-3′ 
 Reverse: 5′- CAGCGAAGCCAGCCAGAA -3′ 
Mouse MCP-1 Forward: 5′- GTCTGTGCTGACCCCAAGAAG-3′ 
 Reverse: 5′- TGGTTCCGATCCAGGTTTTTA-3′ 
Mouse MIP-1α Forward: 5′-CCCGAGCAACACCATGAAG-3′ 
 Reverse: 5′- CCACGAGCAAGAGGAGAGAGA-3′ 
Mouse MIP-2 Forward: 5′- TGGGCTGCTGTCCCTCAA -3′ 
 Reverse: 5′- CCCGGGTGCTGTTTGTTTT-3′ 
Mouse HDAC1 Forward: 5′- GTGGCTACACCATCCGGAAT-3′ 
 Reverse: 5′-GGCCACCGCTGTTTCGTA-3′ 
Mouse HDAC2 Forward: 5′- CGGTGTTTGATGGACTCTTTGA-3′ 
 Reverse: 5′- CACAGCCCCAGCAACTGAA-3′ 
Mouse HDAC3 Forward: 5'-CCCCGATGTGGGCAACT-3' 
 Reverse: 5'-AGGCGATGAGGTTTCATTGG-3' 
Mouse HDAC4 Forward: 5′- CACTGACGCTGCTAGCAATGA-3′ 
 Reverse: 5′- TCACACGGGCAGGATTCA-3′ 
Mouse HDAC5 Forward: 5'-CGCCTCCCTCCTACAAATTG-3' 
 Reverse: 5'-GGAAAGTCATCACGGCTGTCA-3' 
Mouse HDAC6 Forward: 5'-GACAGCGAAAGAGTAGGCACAA-3' 
 Reverse: 5'-AGGTGGCGCTGGATTCC-3' 
Mouse HDAC7 Forward: 5'-GCCTACCCTGACGGCTATCC-3' 
 Reverse: 5'-CCTGGTCCCCTACCCAGATC-3' 
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Mouse HDAC8 Forward: 5'-CGGCCAGACCGCAATG-3' 
 Reverse: 5'-TCCCTTTGATGTAGTTGAGGATTTG-3' 
Mouse HDAC9 Forward: 5'-CAAATGAAGCTGACGCAAATG-3' 
 Reverse: 5'-CATCGCAGCATCTGATTGGA-3' 
Mouse HDAC10 Forward: 5'-GGCTGCTCCTCCACCATAATAA-3' 
 Reverse: 5'-GCCCACCTTGACCGATTTC-3' 
Mouse HDAC11 Forward: 5'-TGGGCATGAGCGAGACTTC-3' 
 Reverse: 5'-GCGGTTGTAAACATCCATGATG-3' 
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